

Name:
 Address:
 Zip code, City:
 Date of birth:
 Phone:

Patient Informed Consent and Ordering by the Patient

My attending physician has given me the **patients and doctors information sheet for the individual testing of tumors for patients with advanced cancer**. I was thoroughly informed, that since recently the possibility to predict drug response for anticancer pharmaceuticals by means of the Oncotest GS Array* analysis exists. This Oncotest GS Array* analysis can reveal which drugs are effective or ineffective for a specific tumor disease with a high reliability. This new technology allows the investigation of targeted and cytotoxic drugs and has an enormous potential to improve the efficacy of a chemotherapy. A total of 1600 genes are determined for their characteristics. However, these predictions must be further validated in prospective clinical trials. We cannot pledge for a tumor response in each individual case. Currently the Oncotest GS Array represents a research tool and requires further clinical validation.

I agree, to perform this investigation as the attending physician has requested on the requisition slip. Therefore, live tumor cells must be excised through a tissue aspiration or through an operation.

Placing of order:

I authorize the Oncotest to perform the sensitivity testing according to the requisition slip. The basic costs for the isolation of RNA, the PCR procedure and a detailed medical report are: 375 USD. Transportation costs are accepted by Oncotest. The costs for the testing of the individual compounds including the basic costs are for:

8 pharmaceuticals	price: 2.100 USD
12 pharmaceuticals	price: 3.200 USD

always including Avastin and Erbitux.

The exclusive analysis of Avastin and/or Erbitux is also possible. The costs are:

Avastin	price: 1.500 USD
Erbitux	price: 1.500 USD
Avastin + Erbitux	price: 1.800 USD

It takes at least 2 month to evaluate an ongoing Avastin or Erbitux treatment of the patient. The costs for this 2 month treatment add up to about 8,000 € for an Avastin treatment and to about 10,000 € for an Erbitux treatment, not including the costs for a concomitant chemotherapy. Today, there is a growing demand for the above mentioned biomarker analysis. This biomarker analysis helps to reduce costs and side effects in the case a therapy is not succesful.

The costs for the above mentioned biomaker analysis are covered by the patient. A detailed invoice will be send to the patient.

I confirm my agreement, that the tumor sample which was sent and the data about my previous diagnosis and treatment course, as well as my future treatment and data about treatment efficacy are available to Oncotest. All delivered personal data are bound to the legal requirement concerning confidential medical communication. Delivery of data is important for further evaluation of our predictive gene signatures. Residual tumor tissue that is no longer required for the biomarker analysis can be used for research purposes by Oncotest, i.a. to test the efficacy of novel antitumor compounds. This will help to improve cancer treatment in the future.

 (Place and Date of Issue) Prof. Dr. H. H. Fiebig

 (Place and Date of Issue) Patient's Signature